These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

334 related articles for article (PubMed ID: 23172002)

  • 21. Progressive disability and prefrontal shrinkage in schizophrenia patients with poor outcome: A 3-year longitudinal study.
    Dusi N; Bellani M; Perlini C; Squarcina L; Marinelli V; Finos L; Altamura CA; Ruggeri M; Brambilla P
    Schizophr Res; 2017 Jan; 179():104-111. PubMed ID: 27624681
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Brain tissue changes and antipsychotic medication.
    Puri BK
    Expert Rev Neurother; 2011 Jul; 11(7):943-6. PubMed ID: 21721911
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Hypofrontality and negative symptoms in schizophrenia: synthesis of anatomic and neuropsychological knowledge and ecological perspectives].
    Semkovska M; Bédard MA; Stip E
    Encephale; 2001; 27(5):405-15. PubMed ID: 11760690
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The course of brain abnormalities in schizophrenia: can we slow the progression?
    van Haren NE; Cahn W; Hulshoff Pol HE; Kahn RS
    J Psychopharmacol; 2012 May; 26(5 Suppl):8-14. PubMed ID: 21730018
    [TBL] [Abstract][Full Text] [Related]  

  • 25. No progressive brain changes during a 1-year follow-up of patients with first-episode psychosis.
    Haukvik UK; Hartberg CB; Nerland S; Jørgensen KN; Lange EH; Simonsen C; Nesvåg R; Dale AM; Andreassen OA; Melle I; Agartz I
    Psychol Med; 2016 Feb; 46(3):589-98. PubMed ID: 26526001
    [TBL] [Abstract][Full Text] [Related]  

  • 26. What is the evidence for changes in cognition and functioning over the lifespan in patients with schizophrenia?
    Harvey PD
    J Clin Psychiatry; 2014; 75 Suppl 2():34-8. PubMed ID: 24919170
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Review of cognition and brain structure in schizophrenia: profiles, longitudinal course, and effects of treatment.
    Flashman LA; Green MF
    Psychiatr Clin North Am; 2004 Mar; 27(1):1-18, vii. PubMed ID: 15062627
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Hippocampal and amygdala volumes according to psychosis stage and diagnosis: a magnetic resonance imaging study of chronic schizophrenia, first-episode psychosis, and ultra-high-risk individuals.
    Velakoulis D; Wood SJ; Wong MT; McGorry PD; Yung A; Phillips L; Smith D; Brewer W; Proffitt T; Desmond P; Pantelis C
    Arch Gen Psychiatry; 2006 Feb; 63(2):139-49. PubMed ID: 16461856
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Remission and recovery during the first outpatient year of the early course of schizophrenia.
    Ventura J; Subotnik KL; Guzik LH; Hellemann GS; Gitlin MJ; Wood RC; Nuechterlein KH
    Schizophr Res; 2011 Oct; 132(1):18-23. PubMed ID: 21764563
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Recovery from schizophrenia: results from a 1-year follow-up observational study of patients in symptomatic remission.
    Bobes J; Ciudad A; Alvarez E; San L; Polavieja P; Gilaberte I
    Schizophr Res; 2009 Nov; 115(1):58-66. PubMed ID: 19729283
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The natural history and pathophysiology of treatment resistant schizophrenia.
    Sheitman BB; Lieberman JA
    J Psychiatr Res; 1998; 32(3-4):143-50. PubMed ID: 9793867
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Progressive structural brain changes in schizophrenia.
    Puri BK
    Expert Rev Neurother; 2010 Jan; 10(1):33-42. PubMed ID: 20021319
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Insight across mental disorders: A multifaceted metacognitive phenomenon.
    Konstantakopoulos G
    Psychiatriki; 2019; 30(1):13-16. PubMed ID: 31115349
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Lay health supporters aided by mobile text messaging to improve adherence, symptoms, and functioning among people with schizophrenia in a resource-poor community in rural China (LEAN): A randomized controlled trial.
    Xu DR; Xiao S; He H; Caine ED; Gloyd S; Simoni J; Hughes JP; Nie J; Lin M; He W; Yuan Y; Gong W
    PLoS Med; 2019 Apr; 16(4):e1002785. PubMed ID: 31013275
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The Core Deficit of Classical Schizophrenia: Implications for Predicting the Functional Outcome of Psychotic Illness and Developing Effective Treatments.
    Liddle PF
    Can J Psychiatry; 2019 Oct; 64(10):680-685. PubMed ID: 31434513
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Exploring predictors of outcome in the psychosis prodrome: implications for early identification and intervention.
    Niendam TA; Jalbrzikowski M; Bearden CE
    Neuropsychol Rev; 2009 Sep; 19(3):280-93. PubMed ID: 19597747
    [TBL] [Abstract][Full Text] [Related]  

  • 37. What do we know about neuropsychological aspects of schizophrenia?
    Palmer BW; Dawes SE; Heaton RK
    Neuropsychol Rev; 2009 Sep; 19(3):365-84. PubMed ID: 19639412
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Meta-analysis of longitudinal studies of cognition in bipolar disorder: comparison with healthy controls and schizophrenia.
    Bora E; Özerdem A
    Psychol Med; 2017 Dec; 47(16):2753-2766. PubMed ID: 28585513
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Long-term outcomes of antipsychotic treatment in patients with first-episode schizophrenia: a systematic review.
    Karson C; Duffy RA; Eramo A; Nylander AG; Offord SJ
    Neuropsychiatr Dis Treat; 2016; 12():57-67. PubMed ID: 26792993
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Corpus callosum volumes in the 5 years following the first-episode of schizophrenia: Effects of antipsychotics, chronicity and maturation.
    de Moura MTM; Zanetti MV; Duran FLS; Schaufelberger MS; Menezes PR; Scazufca M; Busatto GF; Serpa MH
    Neuroimage Clin; 2018; 18():932-942. PubMed ID: 29876278
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.